Clinical Trial

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-22.
Status change: Not Yet Recruiting → Recruiting 2025-10-30
Trial Details
NCT Number NCT07140744
Lead Sponsor Eli Lilly and Company
Conditions Subjective Cognitive Impairment
Enrollment 7,000 participants
Start Date 2025-08-22
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-03